Search hospitals > California > Auburn

Sutter Auburn Faith Hospital

Claim this profile
Auburn, California 95602
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
125 reported clinical trials
9 medical researchers
Photo of Sutter Auburn Faith Hospital in AuburnPhoto of Sutter Auburn Faith Hospital in AuburnPhoto of Sutter Auburn Faith Hospital in Auburn

Summary

Sutter Auburn Faith Hospital is a medical facility located in Auburn, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Auburn Faith Hospital is involved with conducting 125 clinical trials across 287 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.

Area of expertise

1Cancer
Global Leader
Sutter Auburn Faith Hospital has run 60 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Sutter Auburn Faith Hospital has run 26 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
HER2 positive

Top PIs

Clinical Trials running at Sutter Auburn Faith Hospital

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Follicular Lymphoma
Squamous Cell Carcinoma
Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer
Renal Cell Carcinoma
Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Sutter Auburn Faith Hospital?
Sutter Auburn Faith Hospital is a medical facility located in Auburn, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Auburn Faith Hospital is involved with conducting 125 clinical trials across 287 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.